Propanc BiopharmaPPCB
13F holders, Q1 2026 (March 31)6holders +1
4new positions
3sold out
$0.11avg. 13F price*
At the end of Q1 2026, 6 institutions reported holding Propanc Biopharma Inc. (PPCB) in their 13F filings, up 1 from Q4 2025. 4 opened new positions and 3 sold out. The largest holders were UBS Group AG ($19K), Jane Street Group, LLC ($15K) and Marex Group Ltd ($7K).
- Company
- Propanc Biopharma Inc.
- CUSIP
- 74346N701
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $40K |
| Exits | 3 | $22K |
All 13F filers, Q4 2025 → Q1 2026: 385,274 shares bought and 51,769 shares sold, net +333,505 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | New | 182,614 | $19K |
| Jane Street Group, LLC | 0.00% | New | 143,212 | $15K |
| Marex Group Ltd | 0.00% | Add +4.2% | 67,724 | $7K |
| Virtu Financial LLC | 0.00% | New | 40,748 | $4K |
| Sassicaia Capital Advisers LLC | 0.00% | New | 16,000 | $2K |
| XTX Topco Ltd | 0.00% | Reduce -45.3% | 12,098 | $1K |
"% of holder's portfolio" is PPCB's weight in each manager's 13F, not the share of Propanc Biopharma Inc. the manager owns.